Product Code Database
Example Keywords: coat -kindle $8-145
   » » Wiki: Noribogaine
Tag Wiki 'Noribogaine'.
Tag

Noribogaine, also known as O-desmethylibogaine or 12-hydroxyibogamine, is the principal of the . It is thought to be involved in the effects of ibogaine-containing plant extracts, such as Tabernanthe iboga.


Use and effects
Noribogaine is the major active metabolite of the and is thought to be primarily though not exclusively responsible for its effects. In contrast to ibogaine, noribogaine has been limitedly evaluated in humans. It was noted in 2007 that administration of noribogaine to humans had not yet been reported. In 2015 and 2016 however, two of noribogaine were published. It was tested at relatively low doses of 3 to 180mg in these studies. At these doses, no , -like states, or other effects were reported. Similarly, it produced no μ-opioid receptor effects, such as pupil constriction or . At higher doses, in the area of 400 to 1,000mg or more, ibogaine has been reported to produce hallucinogenic effects.Alper, K. R., & Lotsof, H. S. (2007). The use of ibogaine in the treatment of addictions. Psychedelic Medicine: New Evidence for Hallucinogenic Substances as Treatments, 2 Https://s3.ca-central-1.amazonaws.com/ibosafe-pdf-resources/Ibogaine/The+use+of+ibogaine+in+the+treatment+of+addictions.pdf< /ref>
(2025). 9780124339514, Elsevier Science. .


Adverse effects
of noribogaine include visual impairment (specifically increased light perception sensitivity), , , , and QT prolongation.


Pharmacology

Pharmacodynamics
+
Rat
Human
Calf
Human
Calf
Human

Human

Human
Rat
Human

Human
Calf
Human
Mouse/rat

Human

Human

Human
Calf
Calf
Calf
Calf

Human
Calf/guinea pig
Calf/rat
Human
Human
Human
Calf
Human
Human
Human
Human
Bovine
Rat/bovine/human
Human
Human
Human
Human

Bovine
Human
Human
Human
Human
Bovine
Human
Human
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs:
(2025). 9780124695566 .

Noribogaine has been determined to act as a of the κ-opioid receptor (KOR). It activates the (GDP-GTP exchange) signaling pathway with 75% the efficacy of (EC50 = 9 μM), but it is only 12% as efficacious at activating the β-arrestin pathway. With an IC50 value of 1 μM, it can be regarded as an antagonist of the latter pathway.

The β-arrestin signaling pathway is hypothesized to be responsible for the , , or effects of KOR activation. Attenuation of the β-arrestin pathway by noribogaine may be the reason for the absence of these effects, while retaining and properties. This biased KOR activity makes it stand out from the other like and the derivative 18-methoxycoronaridine (18-MC).

Noribogaine is a potent serotonin reuptake inhibitor,

(2015). 9780128006245, Elsevier Science. .
but does not affect the of . Unlike ibogaine, noribogaine does not bind to the sigma-2 receptor.
(2003). 9781440650246, Penguin Publishing Group. .
(2025). 9780120532063, Gulf Professional Publishing. .
Similarly to ibogaine, noribogaine acts as a weak NMDA receptor antagonist and binds to .
(2012). 9780471727606, John Wiley & Sons. .
It has greater affinity for each of the opioid receptors than does ibogaine. Noribogaine has been reported to be a low- serotonin releasing agent, although findings are conflicting and other studies have found that it is inactive as a serotonin releasing agent.

Noribogaine is a inhibitor and appears at least as potent as ibogaine. The inhibition of the hERG potassium channel delays the of cardiac action potentials, resulting in prolongation and, subsequently, in and sudden .

Noribogaine has been reported to be a potent similarly to ibogaine.

Ibogaine and the structurally related are , whereas noribogaine is not or is much less so.


Pharmacokinetics
Noribogaine is highly and shows high penetration in rodents.

The elimination half-life of noribogaine is 24 to 50hours.


History
Noribogaine was first described in the scientific literature by at least 1958. It was first identified and described as a of ibogaine by 1995. The first evaluation of noribogaine in humans was published in 2015.


See also

Page 1 of 1
1
Page 1 of 1
1

Account

Social:
Pages:  ..   .. 
Items:  .. 

Navigation

General: Atom Feed Atom Feed  .. 
Help:  ..   .. 
Category:  ..   .. 
Media:  ..   .. 
Posts:  ..   ..   .. 

Statistics

Page:  .. 
Summary:  .. 
1 Tags
10/10 Page Rank
5 Page Refs